Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS) --Where Does It Begin and Where Does It End? (P4.144)

CONCLUSIONS: Further detailed analysis of progression rate by site of onset, sex, age, treatment will require assimilation of clinic-based datasets of properly analyzed ALS-LAUS patients from multiple clinic sites. The appropriate role of IVIg in ALS-LAUS patients requires further study following explication of the natural history of these patients compared with non-ALS-LAUS patients. The determination as to whether auto-antibodies to additional antigens may play a role in the progression rate of ALS-LAUS compared with sporadic ALS needs to be systematically studied. Study Supported by: Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Langford has nothing to disclose. Dr. Alwan has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Lucas has nothing to disclose. Dr. Nichols has nothing to disclose. Dr. Belcher has nothing to disclose. Dr. Lary has nothing to disclose. Dr. Nemeth has nothing to disclose. Dr. Russo has received personal compensation for activities with Teva Neuroscience and Biogen Idec as a consultant. Dr. Wright has nothing to disclose. Dr. Ward has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Fischer has nothing to disclose. Dr. Bockenek has nothing to disclose. Dr. Desai has received personal...

Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Langford, V., Alwan, M., Smith, N., Lucas, N., Nichols, M., Belcher, S., Lary, C., Nemeth, J., Russo, P., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Sanjak, M. Tags: Neuroepidemiology: ALS Source Type: research